跳至主要内容
临床试验/JPRN-jRCTs031210062
JPRN-jRCTs031210062进行中(未招募)2 期

GM-CSF Inhalation for Nontuberculous Mycobacterial Lung Disease Pilot Trial

Kikuchi Toshiaki0 个研究点目标入组 15 人开始时间: 2021年4月30日最近更新:

试验速览

阶段
2 期
状态
进行中(未招募)
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 ot applicable(—)
性别
All

入选标准

  • Subjects meeting all of the conditions below:
  • 1. Age 20 or more at the time of obtaining informed consent, regardless of gender
  • 2. Information about the name and condition of the disease is appropriately provided in advance
  • 3. Ability to understand the explanation of this trial and give written voluntary consent
  • 4. Meet the diagnostic criteria of nontuberculous mycobacterial lung disease. , , and Mycobacterium avium or M. intracellulare is detected in sputum twice within 2 years.
  • 5. Meet a) or b) below:
  • a) Sustained positive mycobacterial culture test after chemotherapy against nontuberculous mycobacterial lung disease for 6 months or more.
  • b) Withdrawal of chemotherapy against nontuberculous mycobacterial lung disease due to insufficient effectiveness or adverse effects 28 days or more before assessment for eligibility

排除标准

  • Subjects meeting one or more conditions below:
  • 1. 12000/mm3 or more of WBC on enrollment
  • 2. Previously treated with GM-CSF inhalation
  • 3. 60 ml or more per 24 hours of Hemoptysis within 4 weeks
  • 4. Cardiovascular diseases, congestive heart failure/angina pectoris/hemorrhagic diathesis etc., with severe symptoms
  • 5. History of malignant tumor with in 5 years except treated uterine carcinoma in situ and local basal cell carcinoma
  • 6. Systemic corticosteroid therapy with 10 mg/day or more on a prednisolone conversion basis within 3 months or the therapy is expected during this trial
  • 7. Change of chemotherapy regimen against nontuberculous mycobacterial lung disease wihtin 28 days
  • 8. Pregnancy, breast-feeding, or desire for childbearing during this trial
  • 9. Liver dysfunction
  • 10. Renal dysfunction
  • 11. History of severe or unexplainable adverse effect by inhalatoin therapy
  • 12. Incapable of informed consent, subject whose informed consent may not be voluntary
  • 13. Ineligible for this trial at the medical discretion of the principal investigator

研究者

发起方
Kikuchi Toshiaki

相似试验